Protas announces new agreement to streamline clinical trials with GSK
GSK has signed a new three-year agreement with Protas that aims to streamline trials across several core therapeutic areas. Protas…
We’re enabling clinical trials to succeed
There is a pressing need for better ways to detect, prevent and treat common and life-threatening diseases, to save lives, improve health and relieve pressure on healthcare systems around the world. But large-scale, randomised controlled trials (RCTs) have become excessively complex and unsustainably expensive, failing to generate the evidence needed for sound decision making. That’s where we come in.
Our origins
We launched as an independent not-for-profit in 2022 to drive change in clinical trials, specifically targeting common and life-threatening diseases because of the impact they have for millions of people worldwide.
We’re a proudly independent voice, backed up by decades of expertise in designing and delivering successful trials that have global health impact.
A different approach
We have a unique, integrated approach. Through smart trial design and delivery, our clinical trials provide clear answers and enable practical involvement of participants and clinicians. Effective use of data and technology, improves trial quality, efficiency and accessibility through its bespoke configuration for the specific needs of each trial. And through collaborative policy development we work across the clinical trials ecosystem to affect change at scale.
Who we work with
Our mission is to reduce the global burden of common disease through smarter clinical trials, working with regulators, clinicians and patients alike.
The combination of our integrated approach, and the right partnerships, capabilities, systems and processes, means we deliver reliable results, while substantially lowering cost.
We are changing the face of clinical trials for the better.
Oxford University Images / John Cairns
“
We must urgently reduce barriers to the development of better treatments for common diseases. At Protas, we do just that. We’re able to drastically reduce the cost and increase the quality and impact of definitive randomised controlled trials.
Prof Sir Martin Landray
CEO, Protas
Quality and trust
Quality and trust are vital to our work. We are committed to taking a quality-led approach, including implementing a quality management system that received ISO 9001:2015 certification in autumn 2023.
Our information security is of the highest standard, maintaining ISO 27001:2022, Cyber Essentials and Cyber Essentials Plus certifications. We meet the standards of the NHS Data Security and Protection Toolkit, which provides assurance that we are practising good data security and handling personal information correctly.
Involving patients and the public
People are at the heart of what we do. We design and deliver trials not for but with those who are set to benefit from them. It’s also important that our trials reflect the real population – a diverse population – so that results and findings can be translated broadly across all demographics.
We involve patients and the public to inform and shape our trials, including forming our inaugural public advisory group in 2024. The members of this group will represent the experiences of patients and the public, and provide feedback on our trials, to ensure they bring about results that really matter to patient care.
Collaborate with us
We’re interested in partnering with organisations across pharma, biotech, academic research, healthcare provision, charity and investment. Discover how we can accelerate the adoption of innovative treatments and improve lives through smarter clinical trials.
Latest news & stories
Participant centred trials: reducing burden as a moral obligation
Emma Law makes the case for the moral contract that should sit at the heart of every clinical trial.
Annalisa Jenkins awarded OBE
The award was given in recognition of outstanding services to life sciences.